Cytokine News and Research

RSS

Three USU doctoral students to receive Henry M. Jackson Fellowships

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2012-13 academic year. The program, established in 1988, includes two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship. Each fellow receives a stipend and travel support.

28 Sep 2012

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Genome-wide epigenomic screening can pinpoint thyroid disease-associated variants

Genome-wide epigenomic screening can pinpoint disease-associated variants and identify novel genetic-epigenetic interactions in autoimmune thyroid diseases, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.

24 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

ProImmune launches ProStorm in vitro cytokine release assay

ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

18 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Interleukin-18 plays a key role in inflammation

The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options.

7 Sep 2012

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Salivary IL-6 could predict recurrence after surgery in mouth cancer patients

Salivary levels of the proinflammatory cytokine interleukin-6 could be a useful predictor for locoregional recurrence in oral squamous cell carcinoma patients who are treated surgically, report researchers.

23 Aug 2012

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.

14 Aug 2012

Possible molecular link between circadian rhythm disturbances and increased inflammatory response

Scientists have known for some time that throwing off the body's circadian rhythm can negatively affect body chemistry. In fact, workers whose sleep-wake cycles are disrupted by night shifts are more susceptible to chronic inflammatory diseases such as diabetes, obesity and cancer.

2 Aug 2012

Smoking offers no benefits in IBD prevention

Smoking increases the risk for Crohn’s disease but not ulcerative colitis, the results of the largest prospective study of the link between inflammatory bowel disease and the habit confirm.

19 Jul 2012

Researchers discover potential drug targets that might reduce ventilator-induced lung inflammation

When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

19 Jul 2012

Identification of IL-9 antitumor activity in melanoma

High expression of interleukin -9 in immune cells inhibits growth of melanoma, show study findings suggesting a role for this T-cell cytokine in tumor suppression.

13 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

12 Jul 2012

OncoSec establishes UCSF as second enrolling site for OMS-I110 Phase II Merkel cell carcinoma trial

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).

11 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

10 Jul 2012

Specific cytokine levels altered in BD patients

Levels of certain cytokines differ between bipolar disorder patients and mentally healthy individuals, as well as between manic and euthymic patients with the mood disorder, results from a systematic review and meta-analysis show.

10 Jul 2012